非小细胞肺癌新辅助免疫治疗的研究进展

Research progress of neoadjuvant immunotherapy for non-small cell lung cancer

摘要:

肺癌的发病率和死亡率普遍较高，严重威胁大众身体健康。近年来，免疫检查点抑制剂的出现给晚期非小细胞肺癌的治疗带来了新的希望。结合理论基础，科学家推测非小细胞肺癌患者可能受益于新辅助免疫治疗。随着研究的深入， 发现新辅助免疫治疗非小细胞肺癌具有较高的安全性和可行性，并可获得振奋人心的病理缓解率。但目前仍存在缺乏远期预后，以及尚未明确潜在受益人群、合理的治疗方案和疗程等问题。本文对新辅助免疫治疗非小细胞肺癌的发展过程、作用机制、研究现状以及与治疗相关的挑战进行综述。

Abstract:

The morbidity and mortality of lung cancer rank higher, which seriously threatens public health. Recently, the emergence of immune checkpoint inhibitors has brought bright light for the treatment of advanced non-small cell lung cancer (NSCLC). Based on the theoretical basis, it is speculated that NSCLC may benefit from neoadjuvant immunotherapy. With the development of various studies, it is demonstrated that neoadjuvant immu‐ notherapy for NSCLC is safe and feasible, and can contribute greatly to the exciting outcome of pathological re‐ sponse. However, current results do not contain long-term prognosis, distinguish potential beneficiaries, develop a rational therapeutic regimen and course, and so on. In this review, we will conclude the development processes, molecular mechanisms, current research status and treatment-related challenges of neoadjuvant immunotherapy for NSCLC.